Evidence map›Paper›PMID 38705575›Full record

ArticleCancer science2024

LINC00173 silence and estrone supply suppress ER

Yu Xie, Meihua Shan, Jing Yu, Yongjun Du, Chengkun Wu, Shujing Liu, Jiayin Li, Yupeng Xiao, Yan Yan, Ning Li and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yu XieSchool of Medicine, Nankai University, Tianjin, China.
Meihua ShanDepartment of Clinical Biochemistry, Army Medical University (Third Military Medical University), Chongqing, China.
Jing YuSchool of Medicine, Nankai University, Tianjin, China.
Yongjun DuSchool of Medicine, Nankai University, Tianjin, China.
Chengkun WuSchool of Medicine, Nankai University, Tianjin, China.
Shujing LiuSchool of Medicine, Nankai University, Tianjin, China.
Jiayin LiSchool of Medicine, Nankai University, Tianjin, China.
Yupeng XiaoSchool of Medicine, Nankai University, Tianjin, China.
Yan YanTianjin Key Laboratory of Oral and Maxillofacial Function Reconstruction, Hospital of Stomatology, Nankai University, Tianjin, China.
Ning LiInstitute of Disaster and Emergency Medicine, Tianjin University, Tianjin, China.
Junfang QinSchool of Medicine, Nankai University, Tianjin, China.ORCID https://orcid.org/0000-0001-5959-0402
Lan LanDepartment of Integrated Traditional & Western Medicine, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Yue WangSchool of Medicine, Nankai University, Tianjin, China.ORCID https://orcid.org/0000-0002-7116-7604

Funding

National Natural Science Foundation of China 31770968National Natural Science Foundation of China 31800661
6 · The paper itself

Abstract

Persistent activation of estrogen receptor alpha (ERα)-mediated estrogen signaling plays a pivotal role in driving the progression of estrogen receptor positive (ER

Indexed as

Breast NeoplasmsEstrogen Receptor alphaEstroneRNA, Long NoncodingTranscription FactorsAnimalsApoptosisCell Line, TumorCell ProliferationFemaleGene Expression Regulation, NeoplasticGene SilencingHumansMCF-7 CellsMiceNuclear ProteinsESR1 protein, humanEstrogen Receptor alphaEstroneNuclear ProteinsRNA, Long NoncodingTranscription FactorsTumor Necrosis Factor-alphabreast cancerERαestroneLINC00173LITAF

Identifiers

PMID38705575
PMCPMC11247560

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.